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Abstract Early evidence suggests the efficacy of voricona-
zole for chronic pulmonary aspergillosis (CPA). We con-
ducted a prospective, open, multicenter trial to evaluate the
efficacy and safety of voriconazole for proven CPA in
minimally or non-immunocompromised patients. Patients
had CPA confirmed by chest computed tomography (CT)
and/or endoscopy, positive Aspergillus culture from a respi-
ratory sample, and positive serologic test for Aspergillus
precipitins. Patients received voriconazole (200 mg twice
daily) for a period of 6–12 months and were followed for
6 months after the end of therapy (EOT). The primary
endpoint was global success at 6 months, defined as
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complete or partial (≥50 % improvement) radiological re-
sponse and mycological eradication. Forty-one patients with
confirmed CPAwere enrolled. All patients had A. fumigatus
as the etiologic agent. By EOT, five patients had died from
comorbidities and seven had discontinued voriconazole due
to toxicity. The global success rate at 6 months was 13/41
(32 %): 10/19 (53 %) for chronic necrotizing aspergillosis
and 3/22 (14 %) for chronic cavitary aspergillosis (p00.01).
The respective success rates at EOT were 58 and 32 %.
Clinical symptoms and quality of life also improved during
treatment. Voriconazole is effective for CPA, with accept-
able toxicity. The response rate is higher and obtained more
rapidly in necrotizing than cavitary forms.
Introduction
The clinical spectrum of Aspergillus disease ranges from
mild allergic manifestations to rapidly evolving invasive
infections. While less studied, chronic pulmonary aspergil-
losis (CPA) seems to be more frequently encountered in
patients with a history of lung disease.
As chronic disabling disease, CPA primarily affects
middle-aged patients who have a multitude of underlying
pulmonary conditions and who are not (or only minimally)
immunosuppressed [1, 2]. Advances in medical imaging
have allowed better distinction between the different types
of CPA, and, despite some overlap, classification into dis-
tinct entities is possible [1]: simple aspergilloma (fungus
ball), chronic cavitary pulmonary aspergillosis (CCPA; also
known as complex aspergilloma), chronic necrotizing pul-
monary aspergillosis (CNPA; also known as semi-invasive
or subacute invasive aspergillosis), chronic fibrosing pul-
monary aspergillosis (an end result of untreated CCPA and,
occasionally, also CNPA), and tracheobronchial aspergillo-
sis (TBA) [1, 3, 4].
CPA is associated with high morbidity and mortality
[3, 5]. Apart from simple aspergilloma, which can be treated
surgically, antifungal therapy is usually the only treatment
option. Intravenous amphotericin B has demonstrated some
effectiveness in CNPA, but is often poorly tolerated and
difficult to administer for sufficiently long durations [1].
Itraconazole has shown mixed results and a high relapse
rate (over 20 %) [6]. Voriconazole, a second-generation
triazole, is considered to be the treatment of choice for
invasive aspergillosis. Indeed, it has been shown that the
administration of voriconazole in any kind of therapeutic
regimen is a significant prognostic factor for invasive infec-
tion [7–10]. In vitro, minimum inhibitory concentrations
(MICs) against Aspergillus spp. are lower for voriconazole
compared to itraconazole and amphotericin B; in addition,
voriconazole exhibits superior fungicidal activity against A.
fumigatus, the leading cause of aspergillosis [11–13]. Vor-
iconazole is rapidly absorbed with a high oral bioavailability
of 90–96 % in fasting conditions [12] and it penetrates well
into tissues and body fluids, including the lung tissue and
the pulmonary epithelial lining fluid [14].
Preliminary exploratory trials have shown voriconazole to
be effective as primary or salvage therapy for CPA [15–17].
However, no prospective trials have been specifically
designed to evaluate the efficacy of voriconazole in this set-
ting. This multicenter, prospective trial was set up to evaluate,
by means of a centralized review of clinical response and the
use of predefined radiological criteria, the efficacy of vorico-
nazole as a first-line therapy for proven CPA.
Patients and methods
Study design
This prospective, non-comparative trial was conducted in 18
French university hospitals between July 2005 and Decem-
ber 2008. Adult patients with a proven diagnosis of CPA
based on a suitable chest computed tomography (CT) scan
and/or a photographically documented endoscopic lesion,
mycological confirmation with an Aspergillus-positive cul-
ture from a bronchopulmonary specimen, and precipitating
antibodies to Aspergillus in serum (≥2 lines) were included
(the inclusion and exclusion criteria are detailed in the
Supplementary Online Material, Appendix 1). All patients
provided written informed consent and the protocol was
approved by the centralized French ethics committee.
Patients received oral voriconazole 200 mg (100 mg for
patients weighing <40 kg) twice daily for at least 6 months,
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after a loading dose of double the maintenance dose on day
1. After this period, the investigator could continue vorico-
nazole therapy for a maximum of six additional months if
further improvement was expected. All patients were
assessed for safety after 1 month. The study investigators
performed efficacy (clinical, radiological, and mycological
examinations) and safety evaluations every 3 months, which
helped to determine treatment duration. Thus, depending on
the individual patient, the treatment duration was 6, 9, or
12 months (end of therapy, EOT); discontinuations at all
other times were considered as early treatment discontinua-
tions. Discontinuation because of treatment-related toxicity
was at the discretion of the investigators. A follow-up visit
was conducted 6 months after the last day of treatment.
Efficacy analysis
A data review committee consisting of the three principal
investigators (J.C., B.P., P.G.) and one mycologist (C.H.)
classified patients as CCPA, CNPA, or TBA based on the
criteria proposed by Denning et al. [1]. They evaluated
response by chest tomodensitometry or bronchoscopy (for
TBA). Radiological response was defined as: (1) complete,
(2) partial, (3) stabilization, or (4) failure (see Supplemen-
tary Online Material, Appendix 1). Mycological response
was categorized as: (1) eradication, (2) presumed eradica-
tion (assessed at each visit separately) in patients without
sputum production at any given visit, or (3) persistence (i.e.,
sputum or bronchopulmonary sample culture positive for A.
fumigatus). However, due to a lack of a validated scale and
inherent difficulties in distinguishing the disease under
study from that of the underlying lung disease, clinical
response was not included as a component of the primary
endpoint.
The primary endpoint was global success at 6 months,
based on previous findings and defined as complete or
partial (≥50 % improvement) radiological response, and
mycological eradication/presumed eradication. Secondary
efficacy endpoints included global success at 3, 9, and
12 months; clinical response using a 10-cm visual analog
scale for six items (cough, dyspnea, sputum, hemoptysis,
chest pain, and nocturnal awakening); assessment of quality
of life using the St. George’s Hospital respiratory question-
naire; serologic response; all-cause mortality at end of
study; and rate of CPA relapse.
Safety analysis
Vital signs and laboratory investigations (hematology, liver
and renal function tests, serum chemistry, and electrocardio-
gram) were carried out at baseline and at every visit. Ad-
verse events were categorized as mild, moderate, or severe,
and their causality determined by the investigator.
Susceptibility testing
In vitro susceptibility testing was performed for available
baseline strains of Aspergillus to amphotericin B, voricona-
zole, itraconazole, and posaconazole. MICs were deter-
mined using Etest strips (AB Biodisk, bioMérieux), after
48 h of incubation at 35 °C on RPMI 1640 medium supple-
mented with 2 % glucose, according to the manufacturer’s
instructions.
The following interpretative breakpoints were used for
amphotericin B [18], itraconazole, and voriconazole MIC
>2 mg/L (resistant) and for posaconazole MIC >0.5 mg/L
(resistant) [19].
Serologic assessment and response
At study entry, anti-Aspergillus antibodies were detected
using the screening techniques available at each site. All
serum samples collected from each patient at study entry
and at each study visit were sent to a centralized mycology
laboratory for the detection of anti-Aspergillus antibodies by
immunoelectrophoresis (further details are provided in the
Supplementary Online Material, Appendix 1).
Statistical analysis
The sample size was determined based on the expected
efficacy response rates; it was calculated that a sample size
of 48 patients was required to demonstrate a response rate
>30 %, which is considered to be a positive response in
phase II trials, with 80 % power at a significance level of
α 0 5 %. For categorical data, 95 % confidence intervals
(CIs) were calculated; differences were assumed as statisti-
cally significant if the upper limits for the respective 95 %
CIs remained below 0. All efficacy analyses were conducted
in the modified intent-to-treat population (mITT), i.e., those
patients who had CPA confirmed by the data review com-
mittee, received ≥1 dose of voriconazole, and underwent ≥1
efficacy assessment. Data were compared between diagno-
ses using Pearson’s χ2 test with p<0.05 indicating statistical
significance. All statistical analyses were carried out using
SAS software (version 8.2; SAS Institute Inc., Cary, NC).
All authors had full access to the primary data and the
data analyses, and vouch for the completeness and accuracy
of the data and analyses presented.
Results
Study population
The patient disposition is summarized in Fig. 1. Fifty-six
patients were screened and 48 received at least one dose of
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voriconazole. Of these 48 patients, 41 had confirmed CPA
and comprised the mITT population. Twenty-two patients
had confirmed CCPA and 19 confirmed CNPA; one patient
with TBA was included into the CNPA group for all analy-
ses, due to the clinical similarities between these two forms.
A. fumigatus was isolated from bronchopulmonary speci-
mens in all patients. At the time of inclusion, immunoelec-
trophoresis revealed at least two anti-A. fumigatus precipitin
lines in all patients, with a mean of 4.9 lines (median of 4
lines; range 2–11).
The demographic and clinical characteristics are summa-
rized in Table 1. The relatively low median body mass index
of 17.3 kg/m2 may reflect the overall poor health status of
the study population. Among the 41 patients in the mITT
population, 32 (78 %) continued voriconazole treatment up
to 6 months and 22 (54 %) received voriconazole beyond
6 months. The mean treatment duration was 8.3 months
(range 5 days to 13.6 months). Fifteen patients (37 %)
received concomitant corticosteroid therapy (inhaled, n012
and/or oral, n06). The proportion of necrotizing and cavi-
tary forms in these patients was similar to those patients who
did not receive corticosteroids and the mITT population.
Inhaled corticosteroids were started prior to the study in all
patients except one, and given at the same dosage for the
duration of the study. Oral corticosteroids were given for the
whole study in three patients because of sarcoidosis (n02)
and chronic obstructive pulmonary disease (COPD) (n01)
and in one patient who received hydrocortisone substitution
for adrenal insufficiency. Two other patients received one to
three short courses of oral corticosteroids for bronchospasm
(n01) or COPD exacerbations (n01).
Thirty-two baseline strains underwent susceptibility test-
ing. Of these, 12/32 (38 %) and 7/31 (23 %) strains
exhibited resistance to amphotericin B and itraconazole,
respectively, while a single strain was cross-resistant to
itraconazole, voriconazole, and posaconazole, with MICs
of >32, 16, and 16 mg/L, respectively (Table 2).
Efficacy analyses
Global success
Global success at 6 months, the primary endpoint of this
study, was reported in 13/41 (32 %) patients (95 % CI, 18.1–
48.1 %): 10/19 (53 %) with CNPA and 3/22 (14 %) with
CCPA (p00.01) (Fig. 2).
Fig. 1 Patient disposition.
mITT modified intent-to-treat;
CPA chronic pulmonary asper-
gillosis; DRC data review com-
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The rate of success was similar after 3 months of treatment
for CNPA (53%) but lower for CCPA (9%). Global success at
EOTwas reported in 18/41 (44 %) patients: 11/19 (58 %) with
CNPA and 7/22 (32 %) with CCPA (p00.09) (Fig. 2). The
mean duration of treatment for patients with global success at
EOT did not differ between patients with CNPA (10 months;
range: 6–13.4) and CCPA (11 months; range: 6.6–12.5).
The success rate at 6 months in patients receiving con-
comitant corticosteroids (20 %) was lower than in patients
who were not receiving concomitant corticosteroids (38 %).
Radiological response
Radiological response was evaluated at EOT for 31 patients
(Figs. 3 and 4). CPAwas considered as controlled (complete
or partial response or stabilization) in all cases, with the
exception of one patient with CCPA (30/31; 97 %). Of the
radiologically evaluable patients, 41 % with CCPA showed
Table 1 Demographic and clinical characteristics of patients in the
modified intent-to-treat population (mITT) (N041)a
Demographic characteristics
Male, n (%) 24 (58.5)
Median age at baseline, years (range) 58.0 (25.7–81.6)
Median BMI, kg/m2 (range) 17.3 (13.2–38.9)
Underlying lung disease/conditionb, n (%)
COPD 18 (43.9)
Prior tuberculosis or mycobacteriosis 13 (31.7)
Bronchiectasis 6 (14.6)
Pneumothorax 5 (12.2)
Prior lung cancer 3 (7.3)
Sarcoidosis 3 (7.3)
Asthma/congenital pulmonary hypoplasia 3 (7.3)
Radiotherapy after-effect 2 (4.9)
Aspergilloma surgery 1 (2.4)
Other 11 (26.8)




Alcohol abuse 4 (9.8)
Diabetes mellitus 2 (4.9)
Other 11 (26.8)
None identified 12 (29.3)
BMI body mass index; COPD chronic obstructive pulmonary disease
a The mean number of patients recruited per centre was 2.3 (median 2;
range 1–5)
b Some patients had two or more underlying diseases/conditions
c Three patients received both inhaled and systemic corticosteroids
Table 2 In vitro susceptibility testing of Aspergillus strains collected
at baseline
MIC50 MIC90 GM Range (mg/L)
Amphotericin B (n032) 1.50 4.00 1.17 0.09–32.00
Itraconazole (n031) 1.50 6.00 1.32 0.05–32.00
Posaconazole (n032) 0.094 0.19 0.12 0.03–16.00
Voriconazole (n032) 0.125 0.25 0.14 0.05–16.00
Fig. 2 Global success of voriconazole therapy at 3 months, 6 months,
and end of treatment. Global success was defined as a complete or
partial (≥50 % improvement) radiological response and mycological
eradication/presumed eradication. CCPA chronic cavitary pulmonary
aspergillosis; CNPA chronic necrotizing pulmonary aspergillosis; M3
3-month visit; M6 6-month visit; EOT end of treatment
Fig. 3 Radiological response at end of treatment (defined as the last
available radiological response for each patient receiving ≥6 months of
treatment). CCPA chronic cavitary pulmonary aspergillosis; CNPA
chronic necrotizing pulmonary aspergillosis
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a complete or partial response and 53 % stabilization; 79 %
with CNPA had a complete or partial response and 21 %
stabilized with voriconazole treatment (Fig. 3).
Clinical response
Improvements in global respiratory symptoms were seen at
6 and 12 months (Fig. 5). A significant improvement in
quality of life was noted at 6 months and at the end of study
(Supplementary Online Material, Table 1).
Mycological response
Evaluation of the mycological response revealed eradica-
tion or presumed eradication of A. fumigatus from the
bronchopulmonary specimens of all patients at both
6 months and at EOT. Eradications at 6 months were
documented in 26 of 32 (81 %) patients who received
study treatment for up to 6 months, and at EOT in 18 of
22 (82 %) patients who continued study treatment be-
yond 6 months. The patient with the pan-azole-resistant
strain had CCPA with a presumed eradication at 6 months
and EOT, and was considered a failure at both timepoints
because of an insufficient radiological response.
At 6 months, 8/29 (28 %) patients had negative serology
and 14 (48 %) showed a marked decrease in their specific
immunologic response (decrease of ≥2 lines). All patients
with CNPA showed improvement compared to 64 % of
patients with CCPA. Overall, the mean number of Aspergil-
lus precipitin lines decreased from 4.9 at baseline to 3.3 at
Fig. 4 Examples of




scan of a patient with chronic
cavitary pulmonary aspergillo-
sis (CCPA) at baseline (a) and
after 6 months of treatment (b),
indicating partial regression of
the mycetoma (asterisk) and of
the adjacent pleural thickening
(arrow). Chest CT scan of a
patient with chronic necrotizing
pulmonary aspergillosis
(CNPA) at baseline (c) and after
6 months of treatment (d), in-
dicating total disappearance of
the left upper lobe focal
consolidation
Fig. 5 Clinical symptoms at 6 months (M6) and 12 months (M12)
measured by a 10-cm visual analog scale (VAS). Significant decreases
were observed at 6 months for cough (a−19.6 mm; 95 % CI, −33.7 to
−5.6) and sputum production (c−14.9 mm; 95 % CI, −29.3 to −0.5),
and at 12 months for cough (b−30.1 mm; 95 % CI, −49.9 to −10.4),
sputum production (d−26.5 mm; 95 % CI, −40.1 to −12.8), and mean
global VAS (e−15.9 mm; 95 % CI, −27.3 to −4.4)
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6 months. However, there was no difference in the respec-
tive results between patients with and without global suc-
cess (Supplementary Online Material, Table 2).
Radiological or mycological relapse was observed at the
6-month post-therapeutic visit in 3/18 (17 %) patients (one
each with CCPA, CNPA, and TBA) who had previously
experienced global success at their respective EOT visits.
Safety analysis
Safety was assessed in all patients who received at least one
dose of voriconazole (n048). Side effects were consistent
with the known adverse-event profile of voriconazole [20]:
patients reported visual disturbances (21 %); photosensitiv-
ity reactions (19 %); blurred vision (12 %); constipation,
vomiting, and γ-glutamyl-transferase increase (10 % each);
chills, decreased appetite, headache, and insomnia (8 %
each); and vertigo, nausea, cholestasis, weight loss, and
anorexia (6 % each). Seven patients discontinued voricona-
zole for toxicity, i.e., grade 3 liver toxicity (n02), grade 1
hyponatremia, QT prolongation (80 ms increase), memory
disorder, insomnia and memory loss, or worsening of gen-
eral condition (n01 each). No death was attributable to drug
toxicity. Five patients died during the study from comorbid-
ities (bacterial pneumonia, pneumothorax, chronic respira-
tory failure, ovarian cancer, or septic shock); no deaths were
attributable to CPA in this study.
Discussion
In our study, voriconazole was found to be effective as a
primary therapy for CPA; global success was observed in 32
and 44 % of patients at 6 months and at ≥6 months of
treatment, respectively. CPA was controlled according to
radiological assessments in 97 % of patients, i.e., in all those
with CNPA and 94 % of those with CCPA. There were also
statistically significant improvements in some CPA-related
symptoms (cough and sputum production), which may more
closely reflect improvements in the inflammatory processes
due to Aspergillus infection.
This is the first study of antifungal therapy for CPA with
an extensive follow-up period to demonstrate a quality-of-
life improvement in patients with severe underlying lung
diseases and comorbid conditions. Prolonged voriconazole
therapy was well tolerated, with adverse events either relat-
ed to the underlying pathology or consistent with the known
side-effect profile of voriconazole [20]. Photosensitivity
reactions occurred in almost 20 % of patients in this study.
The global success rates for CPAwere similar at 3 (29 %)
and 6 (32 %) months following treatment with voriconazole,
suggesting that treatment for 3 months could be sufficient
for some patients, especially those with CNPA. Indeed,
treatment outcome was more frequently favorable and
achieved more rapidly in patients with necrotizing forms
of CPA than in those with CCPA. This could be due to the
fungus having been more exposed to voriconazole in CNPA
than CCPA. Aspergillosis infection develops within paren-
chymal lung tissue in CNPA, whereas it exists within a
cavity surrounded by fibrotic tissue in CCPA [1], thus
potentially hindering the penetration of antifungals into the
site of infection. The marked increase in response rate
among CCPA patients from the 6-month visit to EOT sug-
gests that a longer duration of treatment (>6 months) may be
necessary in patients with cavitary forms of CPA.
Three relapses were observed at the 6-month follow-up
visit, one each in patients with CNPA, CCPA, and TBA. In
the CNPA patient, fungal isolates obtained at initial diagno-
sis and at relapse were different as judged by multilocus
microsatellite analysis (data not shown) [21]. This suggests
that the relapse was due to reinfection with a new strain and
not reactivation of the primary infection.
At baseline, only one strain was found to exhibit pan-
azole resistance (i.e., including voriconazole) among the 32
strains tested. In contrast, resistance to itraconazole (23 %)
and amphotericin B (38 %) were common. The high number
of amphotericin B-resistant strains was unexpected. This
patient population is rarely treated with amphotericin B
and no previous treatment with amphotericin B was reported
in the present study population, although we cannot exclude
this possibility with complete certainty. It has been sug-
gested that the Etest may be better able to differentiate
between amphotericin B-susceptible and -resistant strains
than traditional broth microdilution methods [22]. This
may explain, at least in part, the high number of resistant
strains observed in the present study.
Both resistance to antifungals and pre-existing pulmo-
nary disease may have been important determinants of the
overall outcome in our study. As mentioned above, it was
not possible to evaluate the effect of antifungal resistance, as
there was only one strain with an elevated MIC to vorico-
nazole. Underlying pulmonary diseases were inherent to our
study population and the outcome could have been influ-
enced by the progression of the underlying pulmonary con-
dition rather than therapeutic failure. Other factors may also
have influenced outcome, such as concomitant corticoste-
roid therapy, as shown by the lower success rate in these
patients.
Our findings are consistent with other published obser-
vations of oral voriconazole used in this setting [15–17] and
support the current recommendations of the Infectious Dis-
eases Society of America (IDSA), which give voriconazole
a B grading for CPA therapy in general and CNPA in
particular [23]. Our efficacy results compare favorably, in
terms of treatment success, relapse rate, and radiological
response, with those from prospective clinical trials with
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oral itraconazole for CNPA and aspergilloma [6, 24]. How-
ever, unlike our own study, these trials classified CPA dis-
ease stabilization as a treatment success, which further
underscores the potential efficacy differences between vor-
iconazole and itraconazole. Furthermore, diagnostic criteria,
evaluation of efficacy, and study endpoints were not clearly
defined in the itraconazole studies [6, 24].
The other antifungals evaluated in this setting were oral
posaconazole and intravenous micafungin [25–28]; data
with intravenous amphotericin B are available, but are
sparse and discouraging. In a retrospective case series, pos-
aconazole exhibited a response rate of 61 and 46 % at 6 and
12 months, respectively, where a successful response was
defined as no clinical and/or radiological deterioration, and,
as such, included stable disease [25]. Micafungin was eval-
uated in a retrospective case series, a prospective, non-
comparative study, and a comparative trial with voricona-
zole [26–28]. Although these studies suggest good tolera-
bility and efficacy of micafungin in the treatment of CPA,
the results need to be interpreted with caution. For instance,
treatment duration was short (maximum of 8 weeks in the
open-label study and 4 weeks in the comparative study).
Furthermore, treatment success was defined by subjective
criteria, such as clinical improvement, decreased plasma
levels of inflammatory markers, and “…apparent improve-
ment in the newly appeared lesions on radiological images”
[26–28].
Our trial had some limitations which should be consid-
ered when interpreting the study findings. A comparator or
control group was not included in our study. Our study also
did not include therapeutic drug monitoring or long-term
data on relapses/recurrences or survival status beyond the 6-
month follow-up period. However, the study had several
strengths compared with previous studies of voriconazole
and other antifungals in this setting, such as the prospective
study design, efficacy assessment based on imaging con-
firmed by a data review committee, treatment duration of 6–
12 months, and a definition of global success that included
only complete and partial radiological responses.
This is the first prospective, multicenter study with a
central review of predefined radiological response criteria
to demonstrate the effectiveness of voriconazole therapy in
patients with CPA, particularly those with CNPA. Favorable
treatment response was observed from 3 months onwards in
CNPA patients, but improvement required at least 6–
12 months in CCPA patients. Future studies should evaluate
the value of voriconazole dose adjustments based on plasma
levels, an approach associated with potential improvements
in the efficacy and safety of voriconazole for invasive as-
pergillosis [29].
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